Edwards Lifesciences Corporation $EW is Seilern Investment Management Ltd's 4th Largest Position

Key Points

• Seilern Investment Management cut its Edwards Lifesciences stake by 13% in the second quarter, selling 89,960 shares. The remaining 600,231 shares represent 6.8% of Seilern’s portfolio and make EW its fourth-largest holding.
• Edwards reported quarterly EPS of $0.78, beating the $0.74 consensus estimate, while revenue reached $1.74 billion and grew 13.6% year over year.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $100.27, compared with the reported share price of $89.65.

Seilern Investment Management Ltd decreased its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 13.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 600,231 shares of the medical research company's stock after selling 89,960 shares during the period. Edwards Lifesciences accounts for 6.8% of Seilern Investment Management Ltd's investment portfolio, making the stock its 4th largest holding. Seilern Investment Management Ltd owned about 0.10% of Edwards Lifesciences worth $54,297,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. MV Capital Management Inc. acquired a new position in Edwards Lifesciences in the fourth quarter valued at $26,000. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences during the first quarter worth about $25,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $28,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Shares of EW opened at $89.65 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a market capitalization of $51.62 billion, a price-to-earnings ratio of 51.52, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85. The firm has a 50-day simple moving average of $88.19 and a 200-day simple moving average of $84.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm's revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business's stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 620 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the transaction, the vice president directly owned 40,411 shares of the company's stock, valued at $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 43,539 shares of company stock worth $3,685,364 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research analyst reports. Mizuho upped their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Barclays reaffirmed an "overweight" rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Truist Financial boosted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a "hold" rating in a research note on Thursday, July 16th. Robert W. Baird increased their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a "neutral" rating in a report on Friday, April 24th. Finally, Piper Sandler restated an "overweight" rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source